A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2004
12/09/2004	US20040247657 Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
12/09/2004	US20040247643 A miniature coated tablet or covered rod implant; smaller size and larger payloads than immediate release tablets; veterinary medicine
12/09/2004	US20040247642 Instrument coated with magnesium-based compound for reducing thrombosis
12/09/2004	US20040247639 Topical, local, transdermal or oral administration of a secretory phospholipase A2 inhibitor; menstrual migraine and menorrhagia; improved side effect reduction compared to non-steroidal antiinflammatory agents
12/09/2004	US20040247634 Treatment of parasitic disease
12/09/2004	US20040247633 Novel dermatological composition
12/09/2004	US20040247632 Chitosan microparticles for the topical delivery of water insoluble active agents
12/09/2004	US20040247628 Kit for the preparation of a pharmaceutical composition
12/09/2004	US20040247627 Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent
12/09/2004	US20040247621 Combination therapy using a synergistic mixture of mechlorethamine, nitrogen mustard N-oxide, melphalan, uramustin, ifosfamide, chlorambucil, or cyclophosphamide and an anti-interleukin-6 receptor antibody; anticarcinogenic agents
12/09/2004	US20040247618 Nutrient absorption enhancing compositions and methods
12/09/2004	US20040247603 Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation
12/09/2004	US20040247602 Treating a cancer, in particular breast cancer, that overexpresses Her-2 by administering an ADAM inhibitor; novel variants of ADAM15 and ADAM15; synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds
12/09/2004	US20040247597 Method of treating atherosclerosis and other inflammatory diseases
12/09/2004	US20040247584 Administering an atypical form of protein kinase C, such as PKM zeta or PKC iota/lambda; also treating brain and spinal cord injuries
12/09/2004	US20040247579 Mixed chimerism and tolerance
12/09/2004	US20040247564 Treating a tissue disorder involving a loss and/or apoptosis of cells by administering an agent that induces phosphorylation and/or activation of protein kinase B to cause proliferation; particularly administering a human stromal-derived factor-1 and a G-CSF to cause proliferation of cardiomyocytes
12/09/2004	US20040247560 Improved palatability, especially masking the bitter taste of quinolone antibiotics; particle size of less than 50 mu m. delays the formation of a sediment and means that the sediment is very easy to reagitate.
12/09/2004	US20040247537 Uv-screening peptide-flavonoid conjugates
12/09/2004	US20040247535 Contains mono-, di- or tripotassium phosphate to inactivate dental nerves to relieve temporary pains; not only prevents but blocks the exposure of dentinal tubules; may also contain ursodesoxycholic acid and a humectant such as glycerin, sorbitol , xylitol, polyethylene glycol and/or propylene glycol
12/09/2004	US20040247532 NaCl, KCl, NaHCO3, monobasic or dibasic potassium phosphate saliva substitute; triclosan, chlorhexidine or benzalkonium and salts, or cetylpyridium chloride antiseptic; NaF, Na2PO3F, or xylitol anticariogenic agent; vitamin E acetate, panthenol, dipotassium glycyrrhizinate, or aloe vera extract
12/09/2004	US20040247529 Administering a pulmonary surfactant preparation, including a phosphatide and/or a surfactant protein to artificially respirate a patient suffering from a toxic oxygen concentration; side effect reduction
12/09/2004	US20040245662 Method for preparing submicron particles of antineoplastic agents
12/09/2004	US20040244794 Inhalation device with a pharmaceutical composition
12/09/2004	US20040244713 Method for treating animals or masses of water with compositions comprising quinone compounds
12/09/2004	DE29624506U1 Oral composition for poorly soluble basic drugs and macrolide antibiotics - contains alginate complex matrix and organic acid
12/09/2004	DE10322497A1 Prophylaxis or therapy of hyperacusis symptoms comprises topical application of local anesthetic, e.g. lidocaine, to skin of outer ear
12/09/2004	DE10320732A1 Rapid-acting anesthetics with short duration of action, especially useful during surgical intervention, comprises thiazolo-(3,2-a)-(1,3)-diazepine-3-carboxylic acid derivatives
12/09/2004	DE10312360A1 Active agent combinations of antibiotic and blood thinning agent, useful for combating antibiotic-resistant microorganisms, e.g. in medicinal or disinfectant applications
12/09/2004	DE102004012273A1 Stabile und geschmacksmaskierte pharmazeutische Dosierungsform unter Verwendung von porösen Apatit-Körnern Stable and taste masked pharmaceutical dosage form using porous apatite grains
12/09/2004	CA2820174A1 Low sodium solution for dialysis
12/09/2004	CA2809131A1 Use of s1p
12/09/2004	CA2753318A1 Substituted pyrrole derivatives
12/09/2004	CA2568609A1 Haloethyl urea compounds and their use to attenuate, inhibit or prevent non-cancerous pathogenic cellular proliferation and diseases associated therewith
12/09/2004	CA2568607A1 Haloethyl urea compounds and the use thereof to attenuate, inhibit or prevent cancer cell migration
12/09/2004	CA2532707A1 Novel topical steroid cream formulations
12/09/2004	CA2531319A1 Target-oriented chemotherapy for treating tumors of the sexual organs
12/09/2004	CA2527772A1 Tumor-targeted drug delivery systems and uses thereof
12/09/2004	CA2527759A1 Use of s1p
12/09/2004	CA2527737A1 Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type iidiabetes
12/09/2004	CA2527731A1 Substituted pyrrole derivatives as hmg-coa reductase inhibitors
12/09/2004	CA2527691A1 Condensed ring compound
12/09/2004	CA2527632A1 Benzamide nitrile derivatives
12/09/2004	CA2527583A1 Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
12/09/2004	CA2527522A1 Methods of using nitroxides in conjunction with photosensitizers and sonosensitizers
12/09/2004	CA2527483A1 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
12/09/2004	CA2527431A1 Deramciclane-fumarate tablets
12/09/2004	CA2527429A1 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
12/09/2004	CA2527420A1 Compounds, methods and pharmaceutical compositions for inhibiting parp
12/09/2004	CA2527382A1 Captopril derivatives
12/09/2004	CA2527301A1 Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite
12/09/2004	CA2527195A1 Novel 3-substituted-1,4-benzodiazepines
12/09/2004	CA2527194A1 Novel ureido - and amido-pyrazolone derivatives
12/09/2004	CA2527192A1 Novel imidazole derivatives, the production thereof, and the use of the same as a medicament
12/09/2004	CA2527190A1 Combination of acetylsalicylic acid and alpha-glucosidase inhibitors
12/09/2004	CA2527178A1 New long-acting drug combinations for the treatment of respiratory complaints
12/09/2004	CA2527174A1 Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor
12/09/2004	CA2527168A1 Nitrooxyderivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and antiplatelet activity
12/09/2004	CA2527159A1 3-aminomethyl-pyrrolidines as n-type calcium channel blockers
12/09/2004	CA2527145A1 Use of iron for treating attention deficit hyperactivity disorder in children
12/09/2004	CA2527133A1 Method and composition for stable and controlled delivery of (-)-hydroxycitric acid
12/09/2004	CA2527109A1 Oligo double-stranded rna inhibiting the expression of bcl-2 and medicinal composition containing the same
12/09/2004	CA2527094A1 Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
12/09/2004	CA2527017A1 Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
12/09/2004	CA2526883A1 A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor .alpha.
12/09/2004	CA2526749A1 3-[2-(3-amino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
12/09/2004	CA2526732A1 Q-alkyl macrolide and azalide derivatives and regioselective process for their preparation
12/09/2004	CA2526730A1 Substituted pyrrole derivatives
12/09/2004	CA2526712A1 Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1
12/09/2004	CA2526530A1 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
12/09/2004	CA2526383A1 Methods and materials for treating, detecting, and reducing the risk of developing alzheimer's disease
12/09/2004	CA2526175A1 Medicament for internal application, in particular against cancerous diseases
12/09/2004	CA2525973A1 Combination chemotherapy comprising capecitabine and a liposomal platinum complex
12/09/2004	CA2525952A1 Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
12/09/2004	CA2525908A1 Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases
12/09/2004	CA2525887A1 Combined use of ecteinascidin-743 and platinum antineoplastic compounds
12/09/2004	CA2525865A1 Antimicrobial quaternary ammonium organosilane coatings
12/09/2004	CA2525839A1 Crystalline form of .beta.2 adrenergic receptor agonist
12/09/2004	CA2525695A1 Compositions and foods and drinks containing higher fatty acid derivative
12/09/2004	CA2525692A1 Cosmetic and/or pharmaceutical compositions comprising dimthylsulphone for the cure and prevention of irritation, inflammation and cutaneous erythema
12/09/2004	CA2525282A1 Indole derivatives with an improved antipsychotic activity
12/09/2004	CA2524750A1 Composition comprising progesterone-receptor antagonists and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
12/09/2004	CA2524090A1 Use of tripolidine in providing refreshedness on waking
12/09/2004	CA2519835A1 Method of treating corneal transplant rejection
12/09/2004	CA2514121A1 Composition possessing autonomic nerve function regulating action and use thereof
12/08/2004	EP1484333A1 New aminopropylphosphonous acids
12/08/2004	EP1484330A1 Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
12/08/2004	EP1484328A1 Derivatives of quinolyl-propyl-piperidine and their use as antimicrobial agents
12/08/2004	EP1484327A1 Nitrogenous heterocyclic compound and medicine thereof
12/08/2004	EP1484322A1 Process for producing optically active sulfoxide derivative
12/08/2004	EP1484320A1 Jnk inhibitor
12/08/2004	EP1484319A1 Chain oligolactic acid thioester
12/08/2004	EP1484313A1 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
12/08/2004	EP1484086A2 Composition for preventing and curing the acne comprising zinc gluconate and copper gluconate
12/08/2004	EP1484062A1 Crystalline azithromycin, process for manufacture and pharmaceutical compositions thereof
12/08/2004	EP1484061A1 Drugs containing riboflavin-type compounds
12/08/2004	EP1484060A2 Methods and compositions for restoring conformational stability of a protein of the p53 family
12/08/2004	EP1484059A2 Antiviral composition comprising phenylacetic acid derivatives
12/08/2004	EP1484058A2 Pharmaceutical composition for inhibiting altering gene expression and for inducing differentiation in non-malignant cells
12/08/2004	EP1484057A1 Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain

1 ... 4865 4866 4867 4868 4869 4870 4871 4872 4873 4874 4875 4876 4877 4878 4879 4880 4881 4882 4883 4884 4885 ... 7860